EVALUATION OF EFFECTIVENESS OF ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C, CAUSED BY HCV GENOTYPE 6

EVALUATION OF EFFECTIVENESS OF ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C, CAUSED BY HCV GENOTYPE 6

Objectives: Evaluating the effectiveness of 2 therapeutic schemes for chronic hepatitis C (genotype 6) which combined sofosbuvir and ribavirin, one of them also included pegylated interferon. Materials and methods: The study included 110 patients with chronic hepatitis C (genotype 6), who have under...

Full description

Saved in:

Bibliographic Details
Main Authors:	D. A. Lioznov, N. H. Chung, S. L. Nikolaenko, T. B. Trung, F. T. Lan, N. D. Phong
Format:	Article
Language:	Russian
Published:	Journal Infectology 2017-04-01
Series:	Журнал инфектологии
Subjects:	chronic hepatitis c genotype 6 treatment sofosbuvir vietnam
Online Access:	https://journal.niidi.ru/jofin/article/view/566
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

CLINICAL AND LABORATORY CHARACTERISTICS OF CHRONIC HEPATITIS C IN VIETNAM ON THE EXAMPLE OF HO CHI MINH CITY HEPATOLOGY CLINIC
by: D. A. Lioznov, et al.
Published: (2016-12-01)

Effects of antiviral therapy on reducing the risk of metabolic syndrome in patients with chronic hepatitis C
by: A. F. Novikova, et al.
Published: (2023-07-01)

Real-World Treatment Efficacy and Safety Profile of Sofosbuvir- and Velpatasvir-Based HCV Treatment in South Korea: Multicenter Prospective Study
by: Jae Hyun Yoon, et al.
Published: (2025-07-01)

Variety of genotypes of a HCV virus and outcomes of chronic hepatitis C: results 5 summer supervision in the territory of the Kirov region
by: S. V. Baramzina, et al.
Published: (2014-09-01)

Cost-effectiveness of antiviral therapy in treatment-naive patients with chronic hepatitis C (genotype 1)
by: A. V. Rudakova, et al.
Published: (2017-06-01)

Evaluation of Treatment Response in Chronic Hepatitis C Patients Receiving Sofosbuvir/Velpatasvir/Voxilaprevir: A Multicenter Real-World Experience from Türkiye
by: Umut Devrim Binay, et al.
Published: (2025-06-01)

SVR timelines in hepatitis - C irrespective of viral genotype: An Indian perspective
by: Nambaru Vidya Sagar, et al.
Published: (2025-04-01)

Impact of Sofosbuvir Plus Daclatasvir Therapy on the Frequency of CD200R<sup>+</sup> Dendritic Cells in Chronic Hepatitis C Virus Infection
by: Helal F. Hetta, et al.
Published: (2024-12-01)

Association of multiple mutations in NS5A and NS5B genes and resistance to direct-acting antivirals in chronically infected Egyptian patients with Hepatitis C virus Genotype 4a
by: Gehad M. Mohamed, et al.
Published: (2024-02-01)

Impact of Sofosbuvir/Daclatasvir treatment on glycemic control and lipid profile in diabetic patients with chronic hepatitis C
by: Tamer Fouad, et al.
Published: (2025-07-01)

Cost-effectiveness of antiviral therapy in chronic hepatitis C (G1)
by: A. V. Rudakova, et al.
Published: (2016-02-01)

ANALYSIS OF GENOTYPE, SUBGENOTYPE AND SEROTYPE OF OCCULT HEPATITIS B VIRUS
by: Bülent Çakal, et al.
Published: (2021-07-01)

Hepatitis C virus genotypes and viremia in a tertiary hospital in Istanbul, Turkey
by: Sema Alacam, et al.
Published: (2022-04-01)

Antivirals against HCV infection: the story thus far
by: Ahmad Adebayo Irekeola, et al.
Published: (2022-02-01)

Eradication of hepatitits C virus in patient with cryoglobulinemic vasculitis and mutations D168E, L31V
by: N. V. Dunaeva, et al.
Published: (2020-03-01)

Impact of IL28B genetic variant's and viral genotype on treatment outcome of hepatitis C infected patients
by: Mosin S Khan, et al.
Published: (2018-09-01)

Characteristics of Hepatitis C Epidemic Process in the Republic of Belarus
by: V. S. Vysotskaya, et al.
Published: (2021-01-01)

Co-circulation and genetic characterization of genotype I and II feline bocavirus strains in domestic cats from Northern Vietnam
by: Hieu Van Dong, et al.
Published: (2025-06-01)

Conserved recombination patterns across hepatitis B genotypes: a retrospective study
by: Derek Tshiabuila, et al.
Published: (2025-07-01)

Characteristics of HCV infection in oncohematological patients
by: D. A. Lioznov, et al.
Published: (2020-03-01)

Association between risk factors, basal viral load, virus genotype and the degree of liver fibrosis with the response to the therapy in patients with chronic hepatitis C virus infection
by: Vuković Vuk R., et al.
Published: (2015-01-01)

Genetic polymorphism of hepatitis C virus and risk of hepatocellular carcinoma
by: S. N. Mammayev, et al.
Published: (2014-09-01)

Interleukin 28B polymorphism impact on early HCV kinetics in HCV-infected liver transplant recipients undergoing antiviral therapy
by: V. E. Syutkin, et al.
Published: (2011-12-01)

HCV-related chronic kidney disease in the era of new direct-acting antivirals regimens
by: Jakub Janczura, et al.
Published: (2025-08-01)

Effectiveness and safety of narlaprevir in real clinical practice of chronic hepatitis C
by: V. V. Basina, et al.
Published: (2019-12-01)

Variety of the hepatitis B virus genovariants in the military
by: Yu. V. Ostankova, et al.
Published: (2019-10-01)

Risk of progression and the cause of mortality at chronic viral mixed-hepatitis
by: K. I. Yesmembetov, et al.
Published: (2013-07-01)

Clinical and immunomorphological predictors of the adverse course of chronic hepatitis C
by: I. A. Karabak, et al.
Published: (2020-06-01)

For the question about Molecular Epidemiology of Hepatitis B Virus Infection in the Republic Sakha (Yakutia)
by: A. V. Semenov, et al.
Published: (2016-04-01)

Effectiveness of Glecaprevir/Pibrentasvir in Patients with Chronic HCV-infection Genotypes 1 to 6 in the real-world settings in Russia (EVEREST study)
by: О. I. Sagalova, et al.
Published: (2023-07-01)

Therapy of chronic hepatitis C: Virologic response monitoring
by: Kuljić-Kapulica Nada, et al.
Published: (2010-01-01)

The Genotypes/Subtypes and Antiviral Drug Resistance of the Hepatitis C Virus from Patients in a Tertiary Care Hospital in Nepal
by: Hari Prasad Kattel, et al.
Published: (2025-03-01)

Antiviral therapy and regression of liver fibrosis at chronic hepatitis B
by: D. T. Abdurakhmanov
Published: (2010-02-01)

HCV Ab titer and ALT level indicate occult hepatitis C virus infection in treatment-naive HCV Ab-positive and HCV Ab-negative patients: a 3-year prospective cohort study
by: Ming-Ling Chang, et al.
Published: (2025-08-01)

Maternal hepatitis B e antigen can be an indicator for antiviral prophylaxis of perinatal transmission of hepatitis B virus
by: Ying Lu, et al.
Published: (2021-01-01)

Iron metabolism in chronic hepatitis C patients on antiviral treatment
by: K. V. Zhdanov, et al.
Published: (2014-09-01)

Triple antiviral therapy in patient with liver cirrhosis: complications and options of pharmacological treatment
by: M. V. Mayevskaya, et al.
Published: (2014-08-01)

Antiviral therapy for chronic hepatitis C: is there a time to change existing standards?
by: D. T. Abdurakhmanov
Published: (2009-02-01)

IMPACT OF THE ANTIVIRAL THERAPY ON CARDIAC HEMODYNAMICS IN PATIENTS WITH CHRONIC VIRAL HEPATITIS
by: M. V. Chistyakova, et al.
Published: (2015-09-01)

Analysis of mortality and risk of death in HCV- and HCV/HIV-infected patients with extrahepatic manifestations
by: N. V. Dunaeva, et al.
Published: (2022-07-01)